Avadel Pharmaceuticals (AVDL) Scheduled to Post Earnings on Tuesday

Avadel Pharmaceuticals (NASDAQ:AVDL) is scheduled to release its earnings data before the market opens on Tuesday, November 12th. Analysts expect Avadel Pharmaceuticals to post earnings of ($0.06) per share for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.

Avadel Pharmaceuticals (NASDAQ:AVDL) last released its earnings results on Thursday, August 8th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.03. Avadel Pharmaceuticals had a negative return on equity of 122.64% and a negative net margin of 111.64%. The firm had revenue of $41.50 million for the quarter, compared to analyst estimates of $37.47 million. During the same period in the previous year, the company earned ($0.70) earnings per share. Avadel Pharmaceuticals’s revenue was up 2666.7% compared to the same quarter last year. On average, analysts expect Avadel Pharmaceuticals to post $-1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Avadel Pharmaceuticals Trading Up 1.4 %

Shares of NASDAQ AVDL opened at $15.94 on Friday. Avadel Pharmaceuticals has a twelve month low of $10.25 and a twelve month high of $19.09. The firm has a 50-day moving average of $13.69 and a two-hundred day moving average of $15.18. The company has a market capitalization of $1.53 billion, a price-to-earnings ratio of -13.62 and a beta of 1.47.

Analyst Ratings Changes

AVDL has been the subject of several recent research reports. Oppenheimer increased their target price on shares of Avadel Pharmaceuticals from $29.00 to $30.00 and gave the company an “outperform” rating in a research note on Thursday, October 31st. HC Wainwright reiterated a “buy” rating and set a $27.00 price objective on shares of Avadel Pharmaceuticals in a research report on Thursday, October 31st. Finally, Needham & Company LLC restated a “buy” rating and issued a $22.00 target price on shares of Avadel Pharmaceuticals in a report on Thursday, October 31st. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, Avadel Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $24.71.

About Avadel Pharmaceuticals

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.